AGF logo

Additional Cannabis Research

Allsop, D. J., N. Lintzeris, J. Copeland, A. Dunlop, and I. S. McGregor. 2015. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clinical Pharmacology & Therapeutics 97:571-574.

Andréasson, S., A. Engström, P. Allebeck, and U. Rydberg. 1987. Cannabis and schizophrenia A longitudinal study of swedish conscripts. The Lancet 330:1483-1486.

Bar-Sela, G., M. Vorobeichik, S. Drawsheh, A. Omer, V. Goldberg, and E. Muller. 2013. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evidence-Based Complementary and Alternative Medicine 2013.

Beal, J. E., R. Olson, L. Lefkowitz, L. Laubenstein, P. Bellman, B. Yangco, J. O. Morales, R. Murphy, W. Powderly, and T. F. Plasse. 1997. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management 14:7-14.

Bega, D., T. Simuni, M. S. Okun, X. Chen, and P. Schmidt. 2016. Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of Excellence. Movement Disorders Clinical Practice.

Belyea, D. A., R. Alhabshan, A. M. Del Rio-Gonzalez, N. Chadha, T. Lamba, C. Golshani, K. Merchant, N. Passi, and J. A. Dan. 2016. Marijuana Use Among Patients With Glaucoma in a City With Legalized Medical Marijuana Use. JAMA ophthalmology 134:259-264.

Berman, J. S., C. Symonds, and R. Birch. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112:299-306.

Bhattacharyya, S., J. A. Crippa, P. Allen, R. Martin-Santos, S. Borgwardt, P. Fusar-Poli, K. Rubia, J. Kambeitz, C. O’Carroll, and M. L. Seal. 2012. Induction of psychosis byδ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of general psychiatry 69:27-36.

Bhattacharyya, S., P. D. Morrison, P. Fusar-Poli, R. Martin-Santos, S. Borgwardt, T. Winton-Brown, C. Nosarti, C. Mo'Carroll, M. Seal, and P. Allen. 2010. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764-774.

Blake, D. R., P. Robson, M. Ho, R. W. Jubb, and C. S. McCabe. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:50-52.

Borrelli, F., E. Pagano, B. Romano, S. Panzera, F. Maiello, D. Coppola, L. De Petrocellis, L. Buono, P. Orlando, and A. A. Izzo. 2014. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis:bgu205.

Budney, A. J., J. R. Hughes, B. A. Moore, and P. L. Novy. 2001. MArijuana abstinence effects in marijuana smokers maintained in their home environment. Archives of General Psychiatry 58:917-924.

Calhoun, S. R., G. P. Galloway, and D. E. Smith. 1998. Abuse potential of dronabinol (Marinol®). Journal of psychoactive drugs 30:187-196.

Carroll, C. B., P. G. Bain, L. Teare, X. Liu, C. Joint, C. Wroath, S. G. Parkin, P. Fox, D. Wright, and J. Hobart. 2004. Cannabis for dyskinesia in Parkinson disease A randomized double-blind crossover study. Neurology 63:1245-1250.

Carter, G. T., A. M. Flanagan, M. Earleywine, D. I. Abrams, S. K. Aggarwal, and L. Grinspoon. 2011. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. American Journal of Hospice and Palliative Medicine:1049909111402318.

Castle, D. J. and F. R. Ames. 1996. Cannabis and the brain. Australasian Psychiatry 30:179-183.

Chait, L. D. and J. P. Zacny. 1992. Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans. Psychopharmacology 107:255-262.

Charboneau, E. J., M. S. Dietrich, S. Park, A. Cao, T. J. Watkins, J. U. Blackford, M. M. Benningfield, P. R. Martin, M. S. Buchowski, and R. L. Cowan. 2013. Cannabis cue-induced brain activation correlates with drug craving in limbic and visual salience regions: Preliminary results.

Chen, J., I. Matias, T. Dinh, T. Lu, S. Venezia, A. Nieves, D. F. Woodward, and V. Di Marzo. 2005. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochemical and biophysical research communications 330:1062-1067.

Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt, C. O'Leary, S. Ratcliffe, and I. Nováková. 2010. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological research 32:451-459.

Cooper, Z. D., S. D. Comer, and M. Haney. 2013. Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers. Neuropsychopharmacology 38:1984-1992.

Dahl, R. E. 2004. Adolescent brain development: a period of vulnerabilities and opportunities. Keynote address. Annals of the New York Academy of Sciences 1021:1-22.

DeLisi, L. E. 2008. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Current Opinion in Psychiatry 21:140-150.

Demirakca, T., A. Sartorius, G. Ende, N. Meyer, H. Welzel, G. Skopp, K. Mann, and D. Hermann. 2011. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug and alcohol dependence 114:242-245.

Detyniecki, K. and L. J. Hirsch. 2016. Cannabidiol for epilepsy: trying to see through the haze. The Lancet Neurology 15:235-237.

Devinsky, O., M. R. Cilio, H. Cross, J. Fernandez‐Ruiz, J. French, C. Hill, R. Katz, V. Di Marzo, D. Jutras‐Aswad, and W. G. Notcutt. 2014. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:791-802.

Ellis, R. J., W. Toperoff, F. Vaida, G. Van Den Brande, J. Gonzales, B. Gouaux, H. Bentley, and J. H. Atkinson. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34:672-680.

ElSohly, M. A. and D. Slade. 2005. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life sciences 78:539-548.

Englund, A., P. D. Morrison, J. Nottage, D. Hague, F. Kane, S. Bonaccorso, J. M. Stone, A. Reichenberg, R. Brenneisen, and D. Holt. 2013. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology 27:19-27.

Fasinu, P. S., S. Phillips, M. A. ElSohly, and L. A. Walker. 2016. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.

Filbey, F. M., S. Aslan, V. D. Calhoun, J. S. Spence, E. Damaraju, A. Caprihan, and J. Segall. 2014. Long-term effects of marijuana use on the brain. Proceedings of the National Academy of Sciences:201415297.

Finseth, T. A., J. L. Hedeman, R. P. Brown, K. I. Johnson, M. S. Binder, and B. M. Kluger. 2015. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evidence-Based Complementary and Alternative Medicine 2015.

Flach, A. J. 2002. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Transactions of the American Ophthalmological Society 100:215.

Fridberg, D. J., S. Queller, W.-Y. Ahn, W. Kim, A. J. Bishara, J. R. Busemeyer, L. Porrino, and J. C. Stout. 2010. Cognitive mechanisms underlying risky decision-making in chronic cannabis users. Journal of mathematical psychology 54:28-38.

Fridberg, D. J., P. D. Skosnik, W. P. Hetrick, and B. F. O’Donnell. 2013. Neural correlates of performance monitoring in chronic cannabis users and cannabis-naïve controls. Journal of Psychopharmacology 27:515-525.

Fridberg, D. J., J. M. Vollmer, B. F. O'Donnell, and P. D. Skosnik. 2011. Cannabis users differ from non-users on measures of personality and schizotypy. Psychiatry research 186:46-52.

Friedman, D. and O. Devinsky. 2015. Cannabinoids in the treatment of epilepsy. New England Journal of Medicine 373:1048-1058.

Gertsch, J., M. Leonti, S. Raduner, I. Racz, J.-Z. Chen, X.-Q. Xie, K.-H. Altmann, M. Karsak, and A. Zimmer. 2008. Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences 105:9099-9104.

Gilman, J. M., J. K. Kuster, S. Lee, M. J. Lee, B. W. Kim, N. Makris, A. van der Kouwe, A. J. Blood, and H. C. Breiter. 2014. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. The Journal of Neuroscience 34:5529-5538.

Gloss, D. 2014. Management of substance abuse: Cannabis: World Health Organization.

Green, A. J. and K. De‐Vries. 2010. Cannabis use in palliative care–an examination of the evidence and the implications for nurses. Journal of Clinical Nursing 19:2454-2462.

Green, K., H. Wynn, and K. A. Bowman. 1978. A comparison of topical cannabinoids on intraocular pressure. Experimental eye research 27:239-246.

Gross, D. W., J. Hamm, N. L. Ashworth, and D. Quigley. 2004. Marijuana use and epilepsy Prevalence in patients of a tertiary care epilepsy center. Neurology 62:2095-2097.

Guzman, M. 2003. Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3:745-755.

Hart, C. L., W. Van Gorp, M. Haney, R. W. Foltin, and M. W. Fischman. 2001. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25:757-765.

Hegde, M., C. Santos-Sanchez, C. P. Hess, A. A. Kabir, and P. A. Garcia. 2012. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy & Behavior 25:563-566.

Hermann, D. and M. Schneider. 2012. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Current pharmaceutical design 18:4897-4905.

Hofmann, M. E. and C. J. Frazier. 2013. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Experimental neurology 244:43-50.

Hussain, S. A., R. Zhou, C. Jacobson, J. Weng, E. Cheng, J. Lay, P. Hung, J. T. Lerner, and R. Sankar. 2015. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox–Gastaut syndrome. Epilepsy & Behavior 47:138-141.

Inui, E. 2016. Market watch: Upcoming market catalysts in Q1 2016. Nature Reviews Drug Discovery 15:9-9.

Iversen, L. 2003. Cannabis and the brain. Brain 126:1252-1270.

Izzo, A. A., R. Capasso, G. Aviello, F. Borrelli, B. Romano, F. Piscitelli, L. Gallo, F. Capasso, P. Orlando, and V. Di Marzo. 2012. Inhibitory effect of cannabichromene, a major non‐psychotropic cannabinoid extracted from Cannabis sativa, on inflammation‐induced hypermotility in mice. British journal of pharmacology 166:1444-1460.

Jacobsen, L. K., W. E. Mencl, M. Westerveld, and K. R. Pugh. 2004. Impact of cannabis use on brain function in adolescents. Annals of the New York Academy of Sciences 1021:384-390.

Järvinen, T., D. W. Pate, and K. Laine. 2002. Cannabinoids in the treatment of glaucoma. Pharmacology & therapeutics 95:203-220.

Kalant, H. 2001. Medicinal use of cannabis: history and current status. Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur 6:80-91.

Kaufman, P. L. 1998. Marijuana and glaucoma. Archives of Ophthalmology 116:1512-1513.

Koppel, B. S. 2015. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Neurotherapeutics 12:788-792.

Kuhlen, M., J. I. Hoell, G. Gagnon, S. Balzer, P. T. Oommen, A. Borkhardt, and G. Janßen. 2016. Effective treatment of spasticity using dronabinol in pediatric palliative care. European Journal of Paediatric Neurology 20:898-903.

Lastres-Becker, I., F. Molina-Holgado, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz. 2005. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiology of disease 19:96-107.

Lenroot, R. K. and J. N. Giedd. 2006. Brain development in children and adolescents: insights from anatomical magnetic resonance imaging. Neuroscience & Biobehavioral Reviews 30:718-729.

Leo, A., E. Russo, and M. Elia. 2016. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacological research 107:85-92.

Li, H. L. 1974. Origin and use of Cannabis in Eastern Asia; Linguistic-cultural implications. Economic Botany 28:293-301.

Malchow, B., A. Hasan, P. Fusar-Poli, A. Schmitt, P. Falkai, and T. Wobrock. 2013. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. European archives of psychiatry and clinical neuroscience 263:3-13.

Martin-Santos, R., J. A Crippa, A. Batalla, S. Bhattacharyya, Z. Atakan, S. Borgwardt, P. Allen, M. Seal, K. Langohr, and M. Farre. 2012. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Current pharmaceutical design 18:4966-4979.

Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.

McPartland, J. M., M. Duncan, V. Di Marzo, and R. G. Pertwee. 2015. Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British journal of pharmacology 172:737-753.

McPartland, J. M., I. Matias, V. Di Marzo, and M. Glass. 2006. Evolutionary origins of the endocannabinoid system. Gene 370:64-74.

Mechoulam, R. and E. A. Carlini. 1978. Toward drugs derived from cannabis. Naturwissenschaften 65:174-179.

Mechoulam, R., L. A. Parker, and R. Gallily. 2002. Cannabidiol: an overview of some pharmacological aspects. The Journal of Clinical Pharmacology 42:11S-19S.

Meier, M. H., M. L. Hill, P. J. Small, and S. S. Luthar. 2015. Associations of adolescent cannabis use with academic performance and mental health: A longitudinal study of upper middle class youth. Drug and alcohol dependence 156:207-212.

Mendelson, J. H. and N. K. Mello. 1984. Reinforcing properties of oral Δ 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83:351-356.

Miller, L. L. and R. J. Branconnier. 1983. Cannabis: Effects on memory and the cholinergic limbic system. Psychological Bulletin 93:441.

Mokrysz, C., R. Landy, S. H. Gage, M. R. Munafò, J. P. Roiser, and H. V. Curran. 2016. Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. Journal of Psychopharmacology:0269881115622241.

Morgan, C. J. A., T. P. Freeman, G. L. Schafer, and H. V. Curran. 2010. Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879-1885.

Müller-Vahl, K. R., U. Schneider, A. Koblenz, M. Jöbges, H. Kolbe, T. Daldrup, and H. M. Emrich. 2002. Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry 35:57-61.

Müller-Vahl, K. R., U. Schneider, H. Prevedel, K. Theloe, H. Kolbe, and H. M. Emrich. 2003. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. The Journal of clinical psychiatry 64:459-465.

Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids.

Neff, G. W., C. B. O’Brien, K. R. Reddy, N. V. Bergasa, A. Regev, E. Molina, R. Amaro, M. J. Rodriguez, V. Chase, and L. Jeffers. 2002. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. The American journal of gastroenterology 97:2117-2119.

Niesink, R. J. M. and M. W. van Laar. 2013. Does cannabidiol protect against adverse psychological effects of THC? Frontiers in psychiatry 4.

Novack, G. D. 2016. Cannabinoids for treatment of glaucoma. Current opinion in ophthalmology 27:146-150.

Nucci, C., M. Bari, A. Spanò, M. Corasaniti, G. Bagetta, M. Maccarrone, and L. A. Morrone. 2008. Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Progress in brain research 173:451-464.

Nurmikko, T. J., M. G. Serpell, B. Hoggart, P. J. Toomey, B. J. Morlion, and D. Haines. 2007. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain® 133:210-220.

Pagano, E., P. Orlando, S. Finizio, A. Rossi, L. Buono, F. A. Iannotti, F. Piscitelli, A. A. Izzo, V. Di Marzo, and F. Borrelli. 2016. Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. Biochemical Pharmacology.

Paolicelli, D., V. Direnzo, A. Manni, M. D'Onghia, C. Tortorella, S. Zoccolella, V. Di Lecce, A. Iaffaldano, and M. Trojano. 2015. Long‐Term Data of Efficacy, Safety, and Tolerability in a Real‐Life Setting of THC/CBD Oromucosal Spray‐Treated Multiple Sclerosis Patients. The Journal of Clinical Pharmacology.

Pertwee, R. G. 1999. Pharmacology of cannabinoid receptor ligands. Current medicinal chemistry 6:635-664.

Pertwee, R. G. 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British journal of pharmacology 156:397-411.

Plasse, T. F., R. W. Gorter, S. H. Krasnow, M. Lane, K. V. Shepard, and R. G. Wadleigh. 1991. Recent clinical experience with dronabinol. Pharmacology Biochemistry and Behavior 40:695-700.

Porter, B. E. and C. Jacobson. 2013. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior 29:574-577.

Press, C. A., K. G. Knupp, and K. E. Chapman. 2015. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy & Behavior 45:49-52.

Radwan, M. M., S. A. Ross, D. Slade, S. A. Ahmed, F. Zulfiqar, and M. A. ElSohly. 2008. Isolation and characterization of new Cannabis constituents from a high potency variety. Planta medica 74:267-272.

Rapp, C., H. Bugra, A. Riecher-Rössler, C. Tamagni, and S. Borgwardt. 2012. Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies. Current Pharmaceutical Design 18:5070-5080.

Rapp, C., A. Walter, E. Studerus, H. Bugra, C. Tamagni, M. Röthlisberger, S. Borgwardt, J. Aston, and A. Riecher-Rössler. 2013. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Research: Neuroimaging 214:102-108.

Reddy, D. S. and V. M. Golub. 2016. The Pharmacological Basis of Cannabis Therapy for Epilepsy. Journal of Pharmacology and Experimental Therapeutics 357:45-55.

Ren, Y., J. Whittard, A. Higuera-Matas, C. V. Morris, and Y. L. Hurd. 2009. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. The Journal of Neuroscience 29:14764-14769.

Rog, D. J. 2010. Cannabis-based medicines in multiple sclerosis–a review of clinical studies. Immunobiology 215:658-672.

Rog, D. J., T. J. Nurmikko, T. Friede, and C. A. Young. 2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812-819.

Russo, E. B. 2007. History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & Biodiversity 4:1614-1648.

Russo, E. B. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163:1344-1364.

Russo, E. B. 2016. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Frontiers in Pharmacology 7.

Russo, M., R. De Luca, M. Torrisi, C. Rifici, E. Sessa, P. Bramanti, A. Naro, and R. S. Calabrò. 2016. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study. Age (y) 42:43-49.

Salzet, M., C. Breton, T. Bisogno, and V. Di Marzo. 2000. Comparative biology of the endocannabinoid system. European Journal of Biochemistry 267:4917-4927.

Schubart, C. D., I. E. C. Sommer, W. A. van Gastel, R. L. Goetgebuer, R. S. Kahn, and M. P. M. Boks. 2011. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia research 130:216-221.

Selvarajah, D., R. Gandhi, C. J. Emery, and S. Tesfaye. 2010. Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy Depression is a major confounding factor. Diabetes care 33:128-130.

Shohet, A., A. Khlebtovsky, N. Roizen, Y. Roditi, and R. Djaldetti. 2016. Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease. European Journal of Pain.

Solinas, M., V. Cinquina, and D. Parolaro. 2015. Cannabidiol and Cancer—An Overview of the Preclinical Data.

Solowij, N., M. Walterfang, D. I. Lubman, S. Whittle, V. Lorenzetti, M. Styner, D. Velakoulis, C. Pantelis, and M. Yücel. 2013. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophrenia Research 143:179-184.

Strouse, T. B. 2015. Pot in Palliative Care: What We Need to Know. Journal of palliative medicine 18:7-10.

Substance-Abuse and Mental Health Services Administration. 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD.

Svendsen, K. B., T. S. Jensen, and F. W. Bach. 2004. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bmj 329:253.

Swift, W., A. Wong, K. M. Li, J. C. Arnold, and I. S. McGregor. 2013. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS one 8:e70052.

Szaflarski, J. P. and E. M. Bebin. 2014. Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. Epilepsy & Behavior 41:277-282.

Temple, L. M. 2016. Medical marijuana and pain management. Disease-a-Month 62:346-352.

Tomida, I., R. G. Pertwee, and A. Azuara-Blanco. 2004. Cannabinoids and glaucoma. British journal of ophthalmology 88:708-713.

Trigo, J. M., A. Soliman, G. Staios, L. Quilty, B. Fischer, T. P. George, J. Rehm, P. Selby, A. J. Barnes, and M. A. Huestis. 2016. Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. Journal of addiction medicine.

Tzadok, M., S. Uliel-Siboni, I. Linder, U. Kramer, O. Epstein, S. Menascu, A. Nissenkorn, O. B. Yosef, E. Hyman, and D. Granot. 2016. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure 35:41-44.

van Vliet, S. A. M., R. A. P. Vanwersch, M. J. Jongsma, B. Olivier, and I. H. Philippens. 2008. Therapeutic effects of Δ 9-THC and modafinil in a marmoset Parkinson model. European Neuropsychopharmacology 18:383-389.

Vann, R. E., T. F. Gamage, J. A. Warner, E. M. Marshall, N. L. Taylor, B. R. Martin, and J. L. Wiley. 2008. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ 9-tetrahydrocannabinol. Drug and alcohol dependence 94:191-198.

Venderová, K., E. Růžička, V. Voříšek, and P. Višňovský. 2004. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Movement Disorders 19:1102-1106.

Volicer, L., M. Stelly, J. Morris, J. McLaughlin, and B. J. Volicer. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International journal of geriatric psychiatry 12:913-919.

Volkow, N. D., R. D. Baler, W. M. Compton, and S. R. B. Weiss. 2014. Adverse Health Effects of Marijuana Use. New England Journal of Medicine 370:2219-2227.

Wade, D. T., P. Makela, P. Robson, H. House, and C. Bateman. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 10:434-441.

Walker, J. M., S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sañudo-Peña. 1999. Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences 96:12198-12203.

Walsh, D., J. Kirkova, and M. P. Davis. 2005. The Efficacy and Tolerability of Long-Term Use of Dronabinol in Cancer-Related Anorexia: A Case Series. Journal of Pain and Symptom Management 30:493-495.

Welch, K. A., T. W. Moorhead, A. M. McIntosh, D. G. C. Owens, E. C. Johnstone, and S. M. Lawrie. 2013. Tensor-based morphometry of cannabis use on brain structure in individuals at elevated genetic risk of schizophrenia. Psychological medicine 43:2087-2096.

Whitfield, R. M., L. M. Bechtel, and G. H. Starich. 1997. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcoholism: Clinical and Experimental Research 21:122-127.

Whittle, B. A., G. W. Guy, and P. Robson. 2001. Prospects for new cannabis-based prescription medicines. Journal of Cannabis Therapeutics 1:183-205.

Wilkinson, S. T., R. Radhakrishnan, and D. C. D’Souza. 2016. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal of Clinical Psychiatry 77:1050-1064.

Wilsey, B., T. Marcotte, R. Deutsch, B. Gouaux, S. Sakai, and H. Donaghe. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain 14:136-148.

Wilsey, B., T. Marcotte, A. Tsodikov, J. Millman, H. Bentley, B. Gouaux, and S. Fishman. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The Journal of Pain 9:506-521.

Woodward, M. R., D. G. Harper, A. Stolyar, B. P. Forester, and J. M. Ellison. 2014. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. The American Journal of Geriatric Psychiatry 22:415-419.

Yücel, M., V. Lorenzetti, C. Suo, A. Zalesky, A. Fornito, M. J. Takagi, D. I. Lubman, and N. Solowij. 2016. Hippocampal harms, protection and recovery following regular cannabis use. Translational psychiatry 6:e710.

Yücel, M., N. Solowij, C. Respondek, S. Whittle, A. Fornito, C. Pantelis, and D. I. Lubman. 2008. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of general psychiatry 65:694-701.

Zajicek, J., P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, A. Thompson, and U. M. r. group. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The lancet 362:1517-1526.

Zuardi, A. W. 2008. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista brasileira de psiquiatria 30:271-280.

Zuardi, A. W., J. A. Crippa, J. E. Hallak, S. Bhattacharyya, Z. Atakan, R. Martin-Santos, P. K. McGuire, and F. S. Guimarães. 2012a. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18:5131-5140.

Zuardi, A. W., J. E. C. Hallak, and J. A. S. Crippa. 2012b. Interaction between cannabidiol (CBD) and∆ 9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 219:247-249.

Zwenger, S. and C. Basu. 2008. Plant terpenoids: applications and future potentials. Biotechnol Mol Biol Rev 3:1-7.

Agricultural Genomics Foundation © 2017
Design & hosting by Hyperspace